AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03901872 — intervention group
Intervention type: DEVICE
Intervention: Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis
Description: All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
Study NCT03309735 — intervention group
Intervention type: DRUG
Intervention: Micronized progesterone
Description: Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
Study NCT03309735 — intervention group
Intervention type: DRUG
Intervention: Micronized progesterone
Description: Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
Study NCT03309735 — intervention group
Intervention type: DRUG
Intervention: Dydrogesterone
Description: Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
Study NCT02037230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775
Description: MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
Study NCT02037230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
Study NCT02037230 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
Study NCT00885534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Vinblastine, Temozolomide
Description: Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1.
Study NCT02608671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin adhesive tape
Study NCT02486185 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SCREENING TEST
Description: * Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)
Study NCT01486095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXXESS + Biomatrix Biolimus Eluting stent
Description: NAP
Study NCT01486095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Culotte technique with Xience V or Xience Prime stents
Description: NAP
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet
Description: single rising daily doses
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL solution
Study NCT02256709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, high caloric breakfast
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet high dose
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drinking solution
Study NCT02256709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBP 5371 CL tablet low dose
Study NCT00981058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: 800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal.
Study NCT00981058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles.
Study NCT00981058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles.
Study NCT00981058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles.
Study NCT00981058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles.
Study NCT01210404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filibuvir
Description: Filibuvir, 600mg bid administered along with methadone on days 2-11
Study NCT03823209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
Study NCT03823209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief HIV Prevention Counseling
Description: Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
Study NCT03823209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief HIV Prevention Counseling
Description: Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
Study NCT00704236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)
Description: 50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
Study NCT00704236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02064777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT03725891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT03725891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT03725891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
Study NCT02544581 — intervention group
Intervention type: OTHER
Intervention: Soberlink combined with aftercare services
Description: Soberlink Alcohol Breath Analyzer System combined with aftercare services
Study NCT01168986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulstar Multiple Impulse Therapy
Description: Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
Study NCT01168986 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants perform an exercise to strengthen the deep neck flexors
Study NCT03615443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a comprehensive, non-invasive tumor sequencing test.
Study NCT01206218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOT Regimen
Description: FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Study NCT01206218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLO Regimen or FLOT Regimen
Description: FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
Study NCT01286051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follistim administration
Description: adminstation of FSH for ovulation induction
Study NCT01286051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follistim plus Ganirelix
Description: Follistim plus single injection of ganirelix
Study NCT02949791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
Study NCT02949791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive surgery
Description: Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
Study NCT02949791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intra abdominal pressure HIPEC
Description: Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
Study NCT02949791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intra abdominal pressure HIPEC
Description: Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
Study NCT04816110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mineralized plasmatic matrix with collagen membrane
Description: Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM and covered by collagen membrane
Study NCT04816110 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mineralized plasmatic matrix (MPM) without collagen membrane
Description: Two tubes of 9 ml of patient's venous blood were collected, the tubes were placed in the centrifuge machine at 2500 rpm for 12 minutes. The resultant product consists of the following two layers:~* A yellow plasma liquid on the top of the tube.~* Red blood cells at the bottom. - The yellow part was collected using a syringe and added to a cup that contains the bone grafting material (hydroxyapatite 20% + β-TCP 80%). The whole preparation was mixed for few seconds to obtain MPM.~After implant placement, the buccal bone defect was grafted with MPM.
Study NCT01862237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * blood collection~* Completion of a pre-operative cardiac MRI.~* Completion of a coronary angiography examination~* Completion during the surgery d'une myocardial biopsy,~* Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~* Completion of a cardiac MRI 1 year after surgery.
Study NCT02139007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Study NCT01117363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention (rye porridge or wheat bread)
Description: A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
Study NCT01117363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention (rye porridge or wheat bread)
Description: A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
Study NCT02447302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Study NCT02447302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01974635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Therapy
Description: During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
Study NCT03507569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773
Description: RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
Study NCT03507569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C] Ro15-4513
Description: At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer \[11C\]Ro15-4513.
Study NCT01523041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose administrated subcutaneously (s.c., under the skin)
Study NCT01523041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose administrated subcutaneously (s.c., under the skin)
Study NCT03304938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lavender Oil
Description: The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Study NCT03304938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Study NCT01594216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study NCT01594216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT03487705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: electromyographic essential tremor
Description: * Making a recording electromyographic recording of the essential tremors in each child included at prospective.~* Collect an electromyographic recording of essential tremors already made in each child included at retrospective.
Study NCT00485784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test
Study NCT00485784 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood test
Description: Blood test
Study NCT02149901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine + 480 ml water
Description: 30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
Study NCT02149901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine + 50 ml water
Description: Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
Study NCT02149901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo + 480 ml water (optional)
Description: placebo PO with a pressor (480 ml) dose of drinking water
Study NCT02149901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 50 ml water (optional)
Description: placebo PO with a non-pressor (50 ml) dose of drinking water
Study NCT05808361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: The complex of therapeutic exercises included exercises in the initial position lying, sitting and standing. In active and static motor modes under the control of saturation, blood pressure, heart rate and respiratory rate.~The complex included breathing exercises with the inclusion of compensatory respiratory muscles, elements of sound and drainage gymnastics, and diaphragmatic breathing. Therapeutic gymnastics was carried out in the form of individual lessons with an exercise therapy instructor, a course of 10 procedures, daily, the duration was 20 minutes.
Study NCT05808361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Hardware massage in the electrostatic field with a frequency of 30/60 Hz of the chest area consisted of 10 procedures, daily, the duration of the procedure was 20 minutes.
Study NCT03699215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension \<90 mmHg.
Study NCT03699215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
Study NCT04473287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reflexology practice
Description: Reflexology is a reliable and holistic complementary and alternative treatment method that means that the body's specific glands, organs and regions are stimulated by applying a special pressure with the fingers on the hands, feet and ears. When the literature is analyzed, it has been determined that reflexology is applied effectively before, during and after surgery, including different surgical procedures, and it is emphasized that one of the most important areas is patients who underwent Coronary Artery Bypass Graft (CABG) surgery. In this study, it is thought that reflexology application to patients undergoing CABG surgery on nursing care will contribute to the nursing literature by examining the effect of reflexology on pain, anxiety, fatigue, sleep and physiological parameters.
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1200 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 2 mg/m², D1, D5, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg, D1, D5, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg, D1-D5, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 40 mg, D1-D5, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m², D1, 4 cycles
Study NCT00135499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m², D1, 4 cycles
Study NCT03749837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C- MAC VS
Description: The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
Study NCT03749837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Endoscope
Description: Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
Study NCT03846908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCT
Description: patients will receive fat load with MCT
Study NCT03846908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA
Description: patients will receive fat load with SFA
Study NCT03846908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA
Description: patients will receive fat load with MUFA